

## DAFTAR PUSTAKA

1. Susanti D, Hamidon H, Taher M, Ahmad Rusmili MR, Hamid SA, Zakaria ZA. Lipid Accumulation Modulation by *Garcinia atroviridis* Fruit Extract in 3T3-L1 Adipocyte Cells. *J Biol Act Prod from Nat*. 2020;10(4):303–16.
2. Pamungkas RA, Chamroonsawasdi K. Self-management based coaching program to improve diabetes mellitus self-management practice and metabolic markers among uncontrolled type 2 diabetes mellitus in Indonesia: A quasi-experimental study. *Diabetes Metab Syndr Clin Res Rev*. 2020;14(1):53–61.
3. Ozougwu O. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. *J Physiol Pathophysiol*. 2013;4(4):46–57.
4. Verma S, Hussain ME. Obesity and diabetes: An update. *Diabetes Metab Syndr Clin Res Rev*. 2017;11(1):73–9.
5. Sajjan MP, Hansen BC, Acevedo-Duncan M, Kindy MS, Cooper DR, Farese R V. Roles of hepatic atypical protein kinase C hyperactivity and hyperinsulinemia in insulin-resistant forms of obesity and type 2 diabetes mellitus. *MedComm*. 2021 Mar;2(1):3–16.
6. Cheng IS, Huang SW, Lu HC, Wu CL, Chu YC, Lee SD, et al. Oral hydroxycitrate supplementation enhances glycogen synthesis in exercised human skeletal muscle. *Br J Nutr*. 2012 Apr;107(7):1048–55.
7. Gilbert M. Role of skeletal muscle lipids in the pathogenesis of insulin resistance of obesity and type 2 diabetes. *J Diabetes Investig*. 2021;12(11):1934–41.
8. PERKENI. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia. 1st ed. Soelistijo SA, editor. PB. PERKENI. Jakarta: PB. PERKENI; 2021. 1–104 p.
9. Nurjana MA, Veridiana NN. Hubungan Perilaku Konsumsi dan Aktivitas Fisik dengan Diabetes Mellitus di Indonesia. *Bul Penelit Kesehat*. 2019;47(2):97–106.
10. Riskesdas HK, Diabetes AP, Meningkatkan I, Farid B, Danilyuk P, Melitus D, et al. Riskesdas : Angka Penderita Diabetes di Indonesia Meningkatkan. *Gatra.com* [Internet]. 2021;1–2. Available from: <https://www.gatra.com/news-519540-kesehatan-riskesdas-angka-penderita-diabetes-di-indonesia-meningkat.html>

11. Arifin B, Idrus LR, van Asselt ADI, Purba FD, Perwitasari DA, Thobari JA, et al. Health-related quality of life in Indonesian type 2 diabetes mellitus outpatients measured with the Bahasa version of EQ-5D. *Qual Life Res.* 2019;28(5):1179–90.
12. Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: An updated meta-analysis of 501 022 adult individuals. *Gut.* 2021;70(5):962–9.
13. Guerra S, Gastaldelli A. The role of the liver in the modulation of glucose and insulin in non alcoholic fatty liver disease and type 2 diabetes. *Curr Opin Pharmacol.* 2020;55:165–74.
14. Duan X, Li Y, Liu Q, Liu L, Li C. Epidemiological characteristics, medical costs and healthcare resource utilization of diabetes-related complications among Chinese patients with type 2 diabetes mellitus. *Expert Rev Pharmacoeconomics Outcomes Res.* 2020;20(5):513–21.
15. Yunitasari T et al. The Effectiveness of Four Pillars Management Type 2 Diabetes Mellitus on Knowledge, Attitude, and Behavior of Prolanis Participants. *J Ris Gizi.* 2019;7:1–4.
16. Ramachandran M, Loi B, Mat Ariff N, Chuan NO, Zahari Sham SY, Thambiah SC, et al. Appropriateness of metformin prescription for type 2 diabetes mellitus patients with chronic kidney disease (Stages 3-5). *Malays J Pathol.* 2020;42(1):71–6.
17. Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. *Nat Rev Endocrinol.* 2019;15(10):569–89.
18. Siavash M, Tabbakhian M, Sabzghabae A, Razavi N. Severity of gastrointestinal side effects of metformin tablet compared to metformin capsule in type 2 diabetes mellitus patients. *J Res Pharm Pract.* 2017;6(2):73–6.
19. Baker C, Retzik-Stahr C, Singh V, Plomondon R, Anderson V, Rasouli N. Should metformin remain the first-line therapy for treatment of type 2 diabetes? *Ther Adv Endocrinol Metab.* 2021;12:1–13.
20. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. *Diabetologia.* 2016;59(3):426–35.
21. Saeedi Borujeni MJ, Esfandiary E, Taheripak G, Codoñer-Franch P, Alonso-Iglesias E, Mirzaei H. Molecular aspects of diabetes mellitus: Resistin, microRNA, and exosome. *J Cell Biochem.* 2018;119(2):1257–72.
22. Finni T, Cronin NJ, Mayfield D, Lichtwark GA, Cresswell AG. Effects of muscle activation on shear between human soleus and gastrocnemius muscles. *Scand J Med Sci Sport.* 2017;27(1):26–34.

23. Xu PT, Song Z, Zhang WC, Jiao B, Yu ZB. Impaired translocation of GLUT4 results in insulin resistance of atrophic soleus muscle. *Biomed Res Int.* 2015;2015:1–11.
24. Milanda T, Safrudin A, Samudra G, Sumiwi S, Muchtaridi M. Sub-chronic toxicity of *Garcinia atroviridis* Griff Fruit's ethanol extract on Wistar rats (*Ratus norvegicus*). *J Adv Pharm Technol Res.* 2019;10(4):178–83.
25. Márquez F, Babio N, Bulló M, Salas-Salvadó J. Evaluation of the Safety and Efficacy of Hydroxycitric Acid or *Garcinia cambogia* Extracts in Humans. *Crit Rev Food Sci Nutr.* 2012;52(7):585–94.
26. Lim WF, Nasir SM, Teh LK, James RJ, Izhar MHM, Salleh MZ. The methanolic extract of *garcinia atroviridis* (Mega) reduces body weight and food intake, and improves lipid profiles by altering the lipid metabolism: A rat model. *Turkish J Biol.* 2020;44(6):437–48.
27. Bayu ES, Febrianti W, Damanik RIM. Flower morphology diversity of asam gelugur (*Garcinia atroviridis* griff, ex t. anders) accessions in several districts of North Sumatera, Indonesian. *IOP Conf Ser Earth Environ Sci.* 2018;122(1):1–6.
28. Lumbantobing CJRE, Sumaryati S, Yerizel E, Endang P. Benefits of Asam Gelugur (*Garcinia atroviridis*) Tea as a Source of Antioxidant Compounds on Malondialdehyde Levels in Adults with Obesity. *Am Sci J Eng Technol Sci.* 2017;34(1):198–204.
29. Kuswandi A, Tarawaan V, Goenawan H, Muchtaridi M, Lesmana R. Potential roles of *Garcinia* family as antimetabolic syndrome. *J Adv Pharm Technol Res.* 2022;13(1):1–6.
30. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. *Endocrinol Metab Clin North Am.* 2010;39(3):481–97.
31. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract.* 2019;157:1–10.
32. Aamir AH, Ul-Haq Z, Mahar SA, Qureshi FM, Ahmad I, Jawa A, et al. Diabetes Prevalence Survey of Pakistan (DPS-PAK): Prevalence of type 2 diabetes mellitus and prediabetes using HbA1c: A population-based survey from Pakistan. *BMJ Open.* 2019;9(2):1–9.
33. Lyssenko V, Laakso M. Genetic screening for the risk of type 2 diabetes: Worthless or valuable? *Diabetes Care.* 2013;36(SUPPL.2):120–6.
34. Nethan S, Sinha D, Mehrotra R. Non communicable disease risk factors and their trends in India. *Asian Pacific J Cancer Prev.* 2017;18(7):2005–10.

35. Budiarto W, Sugiharto M. Biaya klaim INA CBGS dan biaya riil penyakit katastrofik rawat inap peserta Jamkesmas di rumah sakit: studi di 10 rumah sakit milik Kementerian Kesehatan. *Bul Penelit Sist Kesehat* [Internet]. 2013;16(1):58–65. Available from: <https://www.neliti.com/publications/21375/biaya-klaim-ina-cbgs-dan-biaya-riil-penyakit-katastrofik-rawat-inap-peserta-jamk>
36. Misra A, Gopalan H, Jayawardena R, Hills AP, Soares M, Reza-Albarrán AA, et al. Diabetes in developing countries. *J Diabetes*. 2019;11(7):522–39.
37. Hidayat B, Ramadani RV, Rudijanto A, Soewondo P, Suastika K, Siu Ng JY. Direct Medical Cost of Type 2 Diabetes Mellitus and Its Associated Complications in Indonesia. *Value Heal Reg Issues*. 2022;28:82–9.
38. Tahapary DL, Pratisthita LB, Fitri NA, Marcella C, Wafa S, Kurniawan F, et al. Challenges in the diagnosis of insulin resistance: Focusing on the role of HOMA-IR and Tryglyceride/glucose index. *Diabetes Metab Syndr Clin Res Rev*. 2022;16(8):102581.
39. Mekala KC, Bertoni AG. Epidemiology of diabetes mellitus. *Transplantation, Bioeng Regen Endocr Pancreas Vol 1*. 2019;1:49–58.
40. Gerich JE. Is Reduced First-Phase Insulin Release the Earliest Detectable Abnormality in Individuals Destined to Develop Type 2 Diabetes? *Diabetes*. 2002 Feb;51(suppl\_1):S117–21.
41. Alkhatib A, Tsang C, Tiss A, Bahorun T, Arefanian H, Barake R, et al. Functional foods and lifestyle approaches for diabetes prevention and management. *Nutrients*. 2017;9(12):1–18.
42. Cavaiola TS, Pettus JH. Management Of Type 2 Diabetes: Selecting Amongst Available Pharmacological Agents. *Endotext* [Internet]. 2000;1:1–15. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28402618>
43. Suits A, Gudoor R, Shubrook JH. Achieving Remission in the Era of Clinical Inertia: What Is Preventing Us from Treating Type 2 Diabetes? *Diabetology*. 2023;4(1):93–107.
44. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, et al. SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule. *J Am Soc Nephrol*. 2011 Jan;22(1):104–12.
45. Grover A, Sharma K, Gautam S, Gautam S, Gulati M, Singh SK. Diabetes and its complications: therapies available, anticipated and aspired. *Curr Diabetes Rev*. 2021 May;17(4):397–420.
46. Haselgrübler R, Stadlbauer V, Stübl F, Schwarzinger B, Rudzionyte I, Himmelsbach M, et al. Insulin Mimetic Properties of Extracts Prepared from *Bellis perennis*. *Molecules*. 2018 Oct;23(10):1–15.

47. Yang J, Wang X, Zhang C, Ma L, Wei T, Zhao Y, et al. Comparative study of inhibition mechanisms of structurally different flavonoid compounds on  $\alpha$ -glucosidase and synergistic effect with acarbose. *Food Chem.* 2021;347:1–11.
48. Home P. The evolution of insulin therapy. *Diabetes Res Clin Pract.* 2021;175:1–9.
49. Rosenstock J, Emral R, Sauque-Reyna L, Mohan V, Trescolí C, Al Sifri S, et al. Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial. *Diabetes Care.* 2021 Oct;44(10):2361–70.
50. Amin IM. Hypoglycemic Effects in Response to Abelmoshus Esculentus Treatment: A Research Framework using STZ-Induced Diabetic Rats. *Int J Biosci Biochem Bioinforma.* 2011;1(1):63–7.
51. Tekula S, Khurana A, Anchi P, Godugu C. Withaferin-A attenuates multiple low doses of Streptozotocin (MLD-STZ) induced type 1 diabetes. *Biomed Pharmacother.* 2018;106:1428–40.
52. Wang Z, Gleichmann H. GLUT2 in pancreatic islets: Crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. *Diabetes.* 1998;47(1):50–6.
53. Antonio-Villa NE, Bello-Chavolla OY, Vargas-Vázquez A, Mehta R, Aguilar-Salinas CA. The combination of insulin resistance and visceral adipose tissue estimation improves the performance of metabolic syndrome as a predictor of type 2 diabetes. *Diabet Med.* 2020;37(7):1192–201.
54. Lim H, Lim YM, Kim KH, Jeon YE, Park K, Kim J, et al. A novel autophagy enhancer as a therapeutic agent against metabolic syndrome and diabetes. *Nat Commun.* 2018;9(1):1–14.
55. Zhang N, Liu X, Zhuang L, Liu X, Zhao H, Shan Y, et al. Berberine decreases insulin resistance in a PCOS rats by improving GLUT4: Dual regulation of the PI3K/AKT and MAPK pathways. *Regul Toxicol Pharmacol.* 2020;110:1–6.
56. Deacon CF. Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes. *Front Endocrinol (Lausanne).* 2019;10:1–14.
57. Pang MD, Goossens GH, Blaak EE. The Impact of Artificial Sweeteners on Body Weight Control and Glucose Homeostasis. *Front Nutr.* 2021;7:1–19.
58. Zhao C, Yang C, Wai STC, Zhang Y, P. Portillo M, Paoli P, et al. Regulation of glucose metabolism by bioactive phytochemicals for the management of type 2 diabetes mellitus. *Crit Rev Food Sci Nutr.* 2019;59(6):830–47.

59. Huang X, Liu G, Guo J, Su ZQ. The PI3K/AKT pathway in obesity and type 2 diabetes. *Int J Biol Sci.* 2018;14(11):1483–96.
60. Jeddi S, Gheibi S, Carlström M, Kashfi K, Ghasemi A. Long-term co-administration of sodium nitrite and sodium hydrosulfide inhibits hepatic gluconeogenesis in male type 2 diabetic rats: Role of PI3K-Akt-eNOS pathway. *Life Sci.* 2021;265(24):1–8.
61. Cui X, Qian DW, Jiang S, Shang EX, Zhu ZH, Duan JA. *Scutellariae radix* and *coptidis rhizoma* improve glucose and lipid metabolism in T2DM rats via regulation of the metabolic profiling and MAPK/PI3K/Akt signaling pathway. *Int J Mol Sci.* 2018;19(11):1–22.
62. Miller WP, Mihailescu ML, Yang C, Barber AJ, Kimball SR, Jefferson LS, et al. The translational repressor 4E-BP1 contributes to diabetes-induced visual dysfunction. *Investig Ophthalmology Vis Sci.* 2016 Mar;57(3):1327–37.
63. Rachdaoui N. Insulin: the friend and the foe in the development of type 2 diabetes mellitus. *Int J Mol Sci.* 2020 Mar;21(5):1–21.
64. Van der Vaart JI, Boon MR, Houtkooper RH. The role of AMPK signaling in brown adipose tissue activation. *Cells.* 2021 May;10(5):1–19.
65. Song Z, Xiaoli A, Yang F. Regulation and metabolic significance of de novo lipogenesis in adipose tissues. *Nutrients.* 2018 Sep;10(10):1383.
66. Fu J, Sun L, Mu Z, Xiu S. Free fatty acids are associated with muscle dysfunction in Chinese adults with type 2 diabetes. *Endocrine.* 2022 Jun;77(1):41–7.
67. Cheng L, Wang J, Dai H, Duan Y, An Y, Shi L, et al. Brown and beige adipose tissue: a novel therapeutic strategy for obesity and type 2 diabetes mellitus. *Adipocyte.* 2021;10(1):48–65.
68. Russo S, Kwiatkowski M, Govorukhina N, Bischoff R, Melgert BN. Meta-inflammation and metabolic reprogramming of macrophages in diabetes and obesity: the importance of metabolites. *Front Immunol.* 2021;12:1–17.
69. Gonzalez-Rellan MJ, Fondevila MF, Fernandez U, Rodríguez A, Varela-Rey M, Veyrat-Durebex C, et al. O-GlcNAcylated p53 in the liver modulates hepatic glucose production. *Nat Commun.* 2021;12(1):1–21.
70. He L, Li Y, Zeng N, Stiles BL. Regulation of basal expression of hepatic PEPCCK and G6Pase by AKT2. *Biochem J.* 2020 Mar;477(5):1021–31.
71. Stoeckman AK, Towle HC. The role of SREBP-1c in nutritional regulation of lipogenic enzyme gene expression. *J Biol Chem.* 2002;277(30):27029–35.
72. Zhao H, Zhang F, Sun D, Wang X, Zhang X, Zhang J, et al. Branched-chain amino acids exacerbate obesity-related hepatic glucose and lipid metabolic disorders via attenuating Akt2 signaling. *Diabetes.* 2020 Jun;69(6):1164–77.

73. Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. *World J Gastroenterol*. 2018 Aug;24(30):3361–73.
74. Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. *Mol Metab*. 2021;50(April):101238.
75. Sun N, Shen C, Zhang L, Wu X, Yu Y, Yang X, et al. Hepatic krüppel-like factor 16 (KLF16) targets PPAR $\alpha$  to improve steatohepatitis and insulin resistance. *Gut*. 2021;70(11):2183–95.
76. Yeo GSH, Chao DHM, Siegert AM, Koerperich ZM, Ericson MD, Simonds SE, et al. The melanocortin pathway and energy homeostasis: from discovery to obesity therapy. *Mol Metab*. 2021;48:1–18.
77. Peng J, Yin L, Wang X. Central and peripheral leptin resistance in obesity and improvements of exercise. *Horm Behav*. 2021;133:1–11.
78. Üner AG, Keçik O, Quaresma PGF, De Araujo TM, Lee H, Li W, et al. Role of POMC and AgRP neuronal activities on glycaemia in mice. *Sci Rep*. 2019;9(1):1–14.
79. Shams R, Ito Y, Miyatake H. Evaluation of the binding kinetics of RHEB with mtORC1 by in-cell and in vitro assays. *Int J Mol Sci*. 2021;22(16):1–14.
80. Stanciu GD, Rusu RN, Bild V, Filipiuc LE, Tamba BI, Ababei DC. Systemic actions of SGLT2 inhibition on chronic mTOR activation as a shared aathogenic mechanism between alzheimer’s disease and diabetes. *Biomedicines*. 2021;9(5):1–19.
81. Benchoula K, Arya A, Parhar IS, Hwa WE. FoxO1 signaling as a therapeutic target for type 2 diabetes and obesity. *Eur J Pharmacol*. 2021;891:1–10.
82. He Q, Yang J, Zhang G, Chen D, Zhang M, Pan Z, et al. Sanhuang Jiangtang tablet protects type 2 diabetes osteoporosis via AKT-GSK3 $\beta$ -NFATc1 signaling pathway by integrating bioinformatics analysis and experimental validation. *J Ethnopharmacol*. 2021;273:1–11.
83. Sztolsztener K, Konstantynowicz-Nowicka K, Harasim-Symbor E, Chabowski A. Time-dependent changes in hepatic sphingolipid accumulation and PI3K/Akt/mTOR signaling pathway in a rat model of NAFLD. *Int J Mol Sci*. 2021;22(22):1–16.
84. Fan J, Liu LY, Liu XZ. Hyperinsulinemia negatively affects the association between insulin resistance and blood pressure. *Nutr Metab Cardiovasc Dis*. 2021;31(12):3359–66.

85. Pereira S, Moore J, Li JX, Yu WQ, Ghanim H, Vlavcheski F, et al. 4-Phenylbutyric acid improves free fatty acid-induced hepatic insulin resistance in vivo. *Endocr Connect*. 2021;10(8):861–72.
86. Jin L, Mo Y, Yue EL, Liu Y, Liu KY. Ibrutinib ameliorates cerebral ischemia/reperfusion injury through autophagy activation and PI3K/Akt/mTOR signaling pathway in diabetic mice. *Bioengineered*. 2021;12(1):7432–45.
87. Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: Clinical implications and adverse effects. *Int J Mol Sci*. 2021;22(7):1–77.
88. Hu C, Tao L, Cao X, Chen L. The solute carrier transporters and the brain: physiological and pharmacological implications. *Asian J Pharm Sci*. 2020;15(2):131–44.
89. Sharma M, Dey CS. AKT isoform-AS160-GLUT4: the defining axis of insulin resistance. *Rev Endocr Metab Disord*. 2021;22(4):973–86.
90. Utama IH, Putu DI, Yudhi G, Si AM. Ekspresi glukosa transporter 4 (GLUT4) pada berbagai organ tikus hiperglikemia. Phd (laporan): Universitas Udayana [Internet]. Vol. 4, Udayana. Bali; 2014. Available from: [https://simdos.unud.ac.id/uploads/file\\_penelitian\\_1\\_dir/1249de7a8e35a57b6efb782cda077a0f.pdf](https://simdos.unud.ac.id/uploads/file_penelitian_1_dir/1249de7a8e35a57b6efb782cda077a0f.pdf)
91. Rohli KE, Boyer CK, Blom SE, Stephens SB. Nutrient regulation of pancreatic islet  $\beta$ -cell secretory capacity and insulin production. *Biomolecules*. 2022;12(2):1–24.
92. James DE, Stöckli J, Birnbaum MJ. The aetiology and molecular landscape of insulin resistance. *Nat Rev Mol Cell Biol*. 2021;22(11):751–71.
93. Deenadayalan A, Subramanian V, Paramasivan V, Veeraraghavan VP, Rengasamy G, Coiambatore Sadagopan J, et al. Stevioside attenuates Insulin resistance in skeletal muscle by facilitating IR/IRS-1/Akt/GLUT 4 signaling pathways: an in vivo and in silico approach. *Molecules*. 2021;26(24):1–22.
94. Stanirowski PJ, Szukiewicz D, Majewska A, Wątroba M, Pyzlak M, Bomba-Opoń D, et al. Placental expression of glucose transporters GLUT-1, GLUT-3, GLUT-8 and GLUT-12 in pregnancies complicated by gestational and type 1 diabetes mellitus. *J Diabetes Investig*. 2022 Mar;13(3):560–70.
95. Bourque DK, Cordeiro D, Nimmo GAM, Kobayashi J, Mercimek-Andrews S. Phenotypic and genotypic spectrum of glucose transporter-1 deficiency syndrome. *Can J Neurol Sci / J Can des Sci Neurol*. 2021;48(6):1–5.
96. Zhang M, Yang H, Yang E, Li J, Dong L. Berberine decreases intestinal GLUT2 translocation and reduces Intestinal glucose absorption in mice. *Int J Mol Sci*. 2021;23(1):1–15.

97. Vrhovac Madunić I, Karin-Kujundžić V, Madunić J, Šola IM, Šerman L. Endometrial glucose transporters in health and disease. *Front Cell Dev Biol.* 2021;9:1–12.
98. Mbatha B, Khathi A, Sibiyana N, Booysen I, Ngubane P. A Dioxidovanadium Complex cis -[VO<sub>2</sub> (obz) py] Attenuates Hyperglycemia in Streptozotocin (STZ)-Induced Diabetic Male Sprague-Dawley Rats via Increased GLUT4 and Glycogen Synthase Expression in the Skeletal Muscle. *Evidence-based Complement Altern Med.* 2022;2022:1–11.
99. Richter EA. Is GLUT4 translocation the answer to exercise-stimulated muscle glucose uptake? *Am J Physiol - Endocrinol Metab.* 2021;320(2):1–14.
100. Yasuda K, Nishikawa W, Iwanaka N, Nakamura E, Seino Y, Tsuda K, et al. Abnormality in fibre type distribution of soleus and plantaris muscles in non-obese diabetic goto-kakizaki rats. *Clin Exp Pharmacol Physiol.* 2002;29(11):1001–8.
101. Mende CW. Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. *Curr Med Res Opin.* 2017;33(3):541–51.
102. Hermann M. *Garcinia atroviridis* [Internet]. CABI Digital Library. 2019 [cited 2023 Jun 6]. p. 5. Available from: <https://doi.org/10.1079/cabicompendium.24845>
103. Taher M, Hamidon H, Susanti D, Zakaria ZA. *Garcinia atroviridis* – A review on phytochemicals and pharmacological properties. *Marmara Pharm J.* 2017;21:38–47.
104. Bayu ES, Lestami A, Kardhinata EH, Rosemary. Phylogenetic relationship of asam gelugur (*Garcinia atroviridis* Griff. ex T. Anders) based on morphological characters in Langkat and Serdang Berdagai, Sumatera Utara. *IOP Conf Ser Earth Environ Sci.* 2018;122(1):1–8.
105. Jamila N, Khan N, Hwang IM, Nho EY, Choi JY, Atlas A, et al. Application of Phytochemical and Elemental Profiling, Chemometric Multivariate Analyses, and Biological Activities for Characterization and Discrimination of Fruits of Four *Garcinia* Species. *Anal Lett.* 2020;53(1–18):122–39.
106. Erenler R, Meral B, Sen O, Elmastas M, Aydin A, Eminagaoglu O, et al. Bioassay-guided isolation, identification of compounds from *origanum rotundifolium* and investigation of their antiproliferative and antioxidant activities. *Pharm Biol.* 2017;55(1):1646–53.
107. Karo-Karo T, Julianti E, Nurminah M. Physicochemical Properties of Gelugur Powder (*Garcinia atroviridis*). *IOP Conf Ser Earth Environ Sci.* 2019;305(1–4).

108. Julianto. Segudang khasiat asam gelugur. *Tabloid sinar tani*. 2016;1–5.
109. Amran AA, Zaiton Z, Faizah O MP. Modulatory effect of *inula racemosa* hook. f. (asteraceae) on experimental atherosclerosis in guinea-pigs. *Singapore Med J*. 2009;50 (3):295–9.
110. Kongchian A, Keawboonlert N, Boonrak T, Lookyee S, Buasri K, Surongkul N, et al. Anti-hyperlipidemia and anti-obesity properties of *garcinia atroviridis* and *camellia sinensis* extracts in high-fat diet mice†1. *Walailak J Sci Technol*. 2020;17(10):1126–38.
111. Mokhtar N, Siddiqui Y, Ali NS. In vitro utilization of bio-active components from the underutilized fruits of *Garcinia atroviridis* for the suppression of *Colletotrichum capsici*. *Int J Agric Biol*. 2018;20(8):1809–17.
112. Roongpisuthipong C, Kantawan R, Roongpisuthipong W. Reduction of adipose tissue and body weight: Effect of water soluble calcium hydroxycitrate in *Garcinia atroviridis* on the short term treatment of obese women in Thailand. *Asia Pac J Clin Nutr*. 2007;16(1):25–9.
113. Galih S, Tiana M, Muchtaridi M. Pharmacological activity of gelugur acid plant (*garcinia atroviridis*): a study. *ijcmes*. 2018;8:406–10.
114. Han N, Li L, Peng M, Ma H. (-)-Hydroxycitric acid nourishes protein synthesis via altering metabolic directions of amino acids in male rats. *Phyther Res*. 2016;5630:1316–29.
115. Kuswandi A, Rusdin A, Tarawan VM, Goenawan H, Lesmana R, Muchtaridi M. Molecular docking study of the major compounds from *Garcinia atroviridis* on human SGLT-2 protein transport using structure-based drug design method. *Int J Appl Pharm*. 2022;14(4):138–43.
116. Ohia SE, Opere CA, LeDay AM, Bagchi M, Bagchi D, Stohs SJ. Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCA-SX). *Mol Cell Biochem*. 2002;238(1–2):89–103.
117. Chuah LO, Yeap SK, Ho WY, Beh BK, Alitheen NB. In vitro and in vivo toxicity of *garcinia* or hydroxycitric acid: A review. *Evidence-based Complement Altern Med*. 2012;2012:1–12.
118. Ismullah MT, Sumiwi A, Milanda T, Muchtaridi M. Binding Mode, Absorption, And Distribution Profile, Mutagenicity and Carcinogenicity of Asam Gelugur (*Garcinia atroviridis* Griff.) Fruit Phytoconstituents as Influenza H7N9 Neuraminidase Inhibitor. *Indones J Pharm Sci Technol J Homepage*. 2019;1(2):39–47.
119. Bigagli E, Lodovici M. Circulating oxidative stress biomarkers in clinical studies on type 2 diabetes and its complications. *Oxid Med Cell Longev*. 2019;2019:1–17.

120. Goudarzvand M, Afraei S, Yaslianifard S, Ghiasy S, Sadri G, Kalvandi M, et al. Hydroxycitric acid ameliorates inflammation and oxidative stress in mouse models of multiple sclerosis. *Neural Regen Res.* 2016;11(10):1610–6.
121. Bathina S, Das UN. Dysregulation of PI3K-Akt-mTOR pathway in brain of streptozotocin-induced type 2 diabetes mellitus in Wistar rats. *Lipids Health Dis.* 2018;17(1):1–11.
122. Sripradha R. Efficacy of garcinia cambogia on body weight, inflammation and glucose tolerance in high fat fed male wistar rats. *J Clin DIAGNOSTIC Res.* 2015;9(2):1–4.
123. Golzarand M, Omidian M, Toolabi K. Effect of Garcinia cambogia supplement on obesity indices: A systematic review and dose-response meta-analysis. *Complement Ther Med.* 2020;52:1–22.
124. Hargunani P, Sharma S, Pai A, Patil B, Jain A. Garcinia cambogia: An ancient fruit rind with recently discovered therapeutic activity. *J Med Pharm Allied Sci.* 2020;9(3):2391–7.
125. Espirito Santo BLS do, Santana LF, Kato Junior WH, de Araújo F de O, Bogo D, Freitas K de C, et al. Medicinal Potential of Garcinia Species and Their Compounds. *Molecules.* 2020;25(19):1–30.
126. Semwal RB, Semwal DK, Vermaak I, Viljoen A. A comprehensive scientific overview of Garcinia cambogia. *Fitoterapia.* 2015;102:134–48.
127. Bayu ES, Lestami A, Kardhinata EH, Rosemary. Phylogenetic relationship of asam gelugur (*Garcinia atroviridis* Griff. ex T. Anders) based on morphological characters in Langkat and Serdang Berdagai, Sumatera Utara. *IOP Conf Ser Earth Environ Sci.* 2018;122(1).
128. Ibuki M, Shoda C, Miwa Y, Ishida A, Tsubota K, Kurihara T. Therapeutic effect of Garcinia cambogia extract and hydroxycitric acid inhibiting hypoxia-inducible factor in a murine model of age-related macular degeneration. *Int J Mol Sci.* 2019;20(20):1–15.
129. Hedrich HJ. Taxonomy and stocks and strains. *Lab Rat*, Second Ed [Internet]. 2005;71–92. Available from: <https://sci-hub.se/https://doi.org/10.1016/B978-0-12-814338-4.00002-7>
130. Modlinska K, Pisula W. The Norway rat, from an obnoxious pest to a laboratory pet. *Elife.* 2020;9:1–13.
131. Dutta S, Sengupta P. Men and mice: Relating their ages. *Life Sci* [Internet]. 2016;152:244–8. Available from: <http://dx.doi.org/10.1016/j.lfs.2015.10.025>

132. Andreollo NA, Santos EF dos, Araújo MR, Lopes LR. Rat's age versus human's age: what is the relationship? *ABCD Arq Bras Cir Dig.* 2012;25(1):49–51.
133. Sengupta P. The laboratory rat: Relating its age with human's. *Int J Prev Med.* 2013;4(6):624–30.
134. Nair A, Jacob S. A simple practice guide for dose conversion between animals and human. *J Basic Clin Pharm.* 2016;7(2):27.
135. Martina SJ, Ramar LAP, Silaban MRI, Luthfi M, Govindan PAP. Antiplatelet effectivity between aspirin with honey on cardiovascular disease based on bleeding time taken on mice. *Open Access Maced J Med Sci.* 2019;7(20):3416–20.
136. Bayat M, Alaei M, Akbari A, Sadegh M, Latifi SA, Parastesh M, et al. A comparative study of the antidiabetic effect of two training protocols in streptozotocin-nicotinamide diabetic rats. *Horm Mol Biol Clin Investig.* 2020;41(2):2–9.
137. Willis SA, Bawden SJ, Malaikah S, Sargeant JA, Stensel DJ, Aithal GP, et al. The role of hepatic lipid composition in obesity-related metabolic disease. *Liver Int.* 2021;41(12):2819–35.
138. Gheibi S, Kashfi K, Ghasemi A. A practical guide for induction of type-2 diabetes in rat: Incorporating a high-fat diet and streptozotocin. *Biomed Pharmacother.* 2017;95(24):605–13.
139. Furman BL. Streptozotocin-induced diabetic models in mice and rats. *Curr Protoc.* 2021;1:1–78.
140. Jiao Y, Wang X, Jiang X, Kong F, Wang S, Yan C. Antidiabetic effects of *Morus alba* fruit polysaccharides on high-fat diet- and streptozotocin-induced type 2 diabetes in rats. *J Ethnopharmacol.* 2017;199:119–27.
141. Okoduwa SIR, Umar IA, James DB, Inuwa HM. Appropriate insulin level in selecting fortified diet-fed, streptozotocin-treated rat model of type 2 diabetes for anti-diabetic studies. *PLoS One.* 2017;12(1):1–21.
142. Cam ME, Hazar-Yavuz AN, Yildiz S, Ertas B, Ayaz Adakul B, Taskin T, et al. The methanolic extract of *Thymus praecox* subsp. *skorpilii* var. *skorpilii* restores glucose homeostasis, ameliorates insulin resistance and improves pancreatic  $\beta$ -cell function on streptozotocin/nicotinamide-induced type 2 diabetic rats. *J Ethnopharmacol.* 2019;231:29–38.
143. Zhang S, Xu M, Zhang W, Liu C, Chen S. Natural polyphenols in metabolic syndrome: Protective mechanisms and clinical applications. *Int J Mol Sci.* 2021;22(11):1–34.

144. Chatatikun M, Supjaroen P, Promlat P, Chantarangkul C, Waranuntakul S, Nawarat J, et al. Antioxidant and tyrosinase inhibitory properties of an aqueous extract of *Garcinia atroviridis* Griff. ex. T. Anderson fruit pericarps. *Pharmacogn J.* 2020;12(1):71–8.
145. Patriani P, Wahyuni TH, Sari T V. Effect of Gelugur acid extract (*Garcinia atroviridis*) on the physical quality of culled chicken meat at different shelf life. *IOP Conf Ser Earth Environ Sci.* 2021;782(2).
146. Pérez-Pérez A, Gambino Y, Maymó J, Goberna R, Fabiani F, Varone C, et al. MAPK and PI3K activities are required for leptin stimulation of protein synthesis in human trophoblastic cells. *Biochem Biophys Res Commun.* 2010;396(4):956–60.
147. Sari MP. Peran Enzim Protease Pada Siklus Sel. *Hermina Heal Sci J.* 2021;1(2):55–63.
148. Hou N, Mai Y, Qiu X, Yuan W, Li Y, Luo C, et al. Carvacrol attenuates diabetic cardiomyopathy by modulating the PI3K/AKT/GLUT4 pathway in diabetic mice. *Front Pharmacol.* 2019 Sep;10:1–15.
149. Heckmann M, Klanert G, Sandner G, Lanzerstorfer P, Auer M, Weghuber J. Fluorescence microscopy-based quantitation of GLUT4 translocation. *Methods Appl Fluoresc.* 2022;10(2):1–13.
150. Jaiswal N, Gavin MG, Quinn WJ, Luongo TS, Gelfer RG, Baur JA, et al. The role of skeletal muscle Akt in the regulation of muscle mass and glucose homeostasis. *Mol Metab.* 2019 Oct;28:1–13.
151. Zhu L, Zhu X, Sun G, Meng X, Wang M, Cui H, et al. Dai-zong-fang, a traditional Chinese herbal formula, ameliorates insulin resistance in db/db mice. *Front Physiol.* 2018;9:1–14.
152. Damasceno DC, Sinzato YK, Bueno A, Dallaqua B, Lima PH, Calderon IMP, et al. Metabolic profile and genotoxicity in obese rats exposed to cigarette smoke. *Obesity.* 2013;21(8):1596–601.
153. Michael F.W Festing. The care and management of laboratory and other reserach animals. In: Hubrecht R, Kirkwood J, editors. *The UFAW hand book on the care and management of laboratory and other research animals.* eight. Wiley-Blackwell; 2010. p. 23–36.
154. Fazlani TA. Blood glucose-lowering mechanism action of fenugreek and metformin in albino rats. *Pure Appl Biol.* 2020 Jun;9(2):1667–72.
155. Naderi A, Zahed R, Aghajanpour L, Amoli FA, Lashay A. Long term features of diabetic retinopathy in streptozotocin-induced diabetic Wistar rats. *Exp Eye Res [Internet].* 2019;184(November 2018):213–20. Available from: <https://doi.org/10.1016/j.exer.2019.04.025>

156. Tarawan VM, Setiawan, Lesmana R, Hanna Goenawan S, Usianti. Seri prosedur dan protokol laboratorium PCR (polymerase chain reaction). Bandung; 2019. (1).
157. MacArthur Clark JA, Sun D. Guidelines for the ethical review of laboratory animal welfare people's republic of China national standard GB/T 35892-2018. *Anim Model Exp Med*. 2020;3(1):103–13.
158. Demir S. Comparison of normality tests in terms of sample sizes under different skewness and kurtosis coefficients. *Int J Assesment Tolls Educ*. 2022;9(2):397–409.
159. Kozak M, Piepho HP. What's normal anyway? residual plots are more telling than significance tests when checking ANOVA assumptions. *J Agron Crop Sci*. 2018;204(1):86–98.
160. Ferrini F, Sannino G, Chiola C, Capparé P, Gastaldi G, Gherlone E. Influence of intra-oral scanner on the marginal accuracy of CAD/CAM single crowns. *Int J Environ Res Public Health*. 2019;16(4):1–9.
161. Tjärnström E, Weber E, Hultgren J, Röcklinsberg H. Emotions and ethical decision-making in animal ethics committees. *Animals*. 2018;8(10):1–19.
162. Mäekivi N. Freedom in captivity: managing zoo animals according to the 'five freedoms.' *Biosemiotics*. 2018;11(1):7–25.
163. Nurmawati T. Studi respon fisiologis dan K kadar gula darah pada tikus putih (*Rattus norvegicus*) yang terpapar streptozotocin (STZ). *J Ners dan Kebidanan (Journal Ners Midwifery)*. 2017;4(3):244–7.
164. Firdaus, Rimbawan, Anna Marliyati S, Roosita K. Streptozotocin, sucrose-induce diabetic male rats model for research approach of gestational diabetes melitus. *J Mkmi*. 2016;12(1):29–34.
165. Vieira R, Souto SB, Sánchez-López E, Machado AL, Severino P, Jose S, et al. Sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndrome—strategies for in vivo administration: Part-II. *J Clin Med*. 2019;8(9):1–20.
166. Hardik G, Razmovski-Naumovski V, Srinivas N. Pharmacology Res Perspec - 2017 - Ghelani - Chronic treatment of R - -lipoic acid reduces blood glucose and lipid levels.pdf. Vol. 5, *Pharmacology Research Perspective*. 2017. p. 1–12.
167. Kirana H, Srinivasan BP. Aqueous extract of *Garcinia indica* choisy restores glutathione in type 2 diabetic rats. *J Young Pharm*. 2010;2(3):265–8.

168. Thazhath SS, Wu T, Bound MJ, Checklin HL, Standfield S, Jones KL, et al. Effects of intraduodenal hydroxycitrate on glucose absorption, incretin release, and glycemia in response to intraduodenal glucose infusion in health and type 2 diabetes: A randomised controlled trial. *Nutrition*. 2016;32(5):553–9.
169. Wielinga PY, Wachters-Hagedoorn RE, Bouter B, van Dijk TH, Stellaard F, Nieuwenhuizen AG, et al. Hydroxycitric acid delays intestinal glucose absorption in rats. *Am J Physiol Gastrointest Liver Physiol*. 2005;288(6):1144–9.
170. Guasch-Ferré M, Santos JL, Martínez-González MA, Clish CB, Razquin C, Wang D, et al. Glycolysis/gluconeogenesis- and tricarboxylic acid cycle-related metabolites, Mediterranean diet, and type 2 diabetes. *Am J Clin Nutr*. 2020;111(4):835–44.
171. Xie C, Wang X, Young RL, Horowitz M, Rayner CK, Wu T. Role of intestinal bitter sensing in enteroendocrine hormone secretion and metabolic control. *Front Endocrinol (Lausanne)*. 2018;9:1–10.
172. Nursakinah, Zulkahiri, Hasnah, Zamree, Shafeera, Razif FH. Nutritional content and in vitro antioxidant potential of *Garcinia atroviridis* (Asam gelugor) leaves and fruits. *Pubmed*. 2012;18(3):363–71.
173. Jia H, Yamashita T, Li X, Kato H. Laurel attenuates dexamethasone-induced skeletal muscle atrophy in vitro and in a rat model. *Nutrients*. 2022;14(10):1–16.
174. Rathor R, Agrawal A, Kumar R, Suryakumar G, Singh SN. Ursolic acid ameliorates hypobaric hypoxia-induced skeletal muscle protein loss via upregulating Akt pathway: an experimental study using rat model. *IUBMB Life*. 2021;73(2):375–89.
175. Ma J, Ye M, Li Y, Chai S, Huang H, Lian X, et al. Zhuanggu zhitong capsule alleviates osteosarcopenia in rats by up-regulating PI3K/Akt/Bcl2 signaling pathway. *Biomed Pharmacother*. 2021;142:1–14.
176. Gu Y, Zheng Q, Fan G, Liu R. Advances in Anti-Cancer Activities of Flavonoids in *Scutellariae radix*: Perspectives on Mechanism. *Int J Mol Sci*. 2022;23(19).
177. Pratiwi YS, Lesmana R, Goenawan H, Sylviana N, Setiawan I, Tarawan VM, et al. Nutmeg extract increases skeletal muscle mass in aging rats partly via IGF1-AKT-mTOR pathway and inhibition of autophagy. *Evidence-based Complement Altern Med*. 2018;2018:1–9.
178. Adibuduge Y, Senevirathne M. Potential of Nutmeg ( *Myristica fragrans* Houtt ) Leaf Extracts as a Source of Functional Ingredients with Antibacterial , Antifungal and Antioxidant Activities. 2023;18(2):221–36.

179. Morita Y, Ishida T, Morisawa S, Jobu K, Ou Y, Fujita H, et al. Juzentaihoto suppresses muscle atrophy and decreased motor function in SAMP8 mice. *Biol Pharm Bull.* 2021;44(1):32–8.
180. Sharma S, Chaudhary P, Sandhir R, Bharadwaj A, Gupta RK, Khatri R, et al. Heat-induced endoplasmic reticulum stress in soleus and gastrocnemius muscles and differential response to UPR pathway in rats. *Cell Stress Chaperones.* 2021;26(2):323–39.
181. Batista TM, Haider N, Kahn CR. Defining the underlying defect in insulin action in type 2 diabetes. *Diabetologia.* 2021;64(5):994–1006.
182. Che Hassan NKN, Taher M, Susanti D. Phytochemical constituents and pharmacological properties of *Garcinia xanthochymus*- a review. *Biomed Pharmacother.* 2018;106(April):1378–89.
183. Liao Z, Zhang J, Liu B, Yan T, Xu F, Xiao F, et al. Polysaccharide from Okra (*Abelmoschus esculentus* (L.) Moench) Improves Antioxidant Capacity via PI3K/AKT Pathways and Nrf2 Translocation in a Type 2 Diabetes Model. *Molecules.* 2019;24(10):1–17.
184. Dantas TL, Alonso Buriti FC, Florentino ER. Okra (*Abelmoschus esculentus* L.) as a potential functional food source of mucilage and bioactive compounds with technological applications and health benefits. *Plants.* 2021;10(8):1–14.
185. Gong W, Zhang N, Cheng G, Zhang Q, He Y, Shen Y, et al. *Rehmannia glutinosa* libosch extracts prevent bone loss and architectural deterioration and enhance osteoblastic bone formation by regulating the IGF-1/PI3K/mTOR pathway in streptozotocin-induced diabetic rats. *Int J Mol Sci.* 2019;20(16):1–18.
186. Guo X, Sun W, Luo G, Wu L, Xu G, Hou D, et al. *Panax notoginseng* saponins alleviate skeletal muscle insulin resistance by regulating the IRS 1–PI 3K– AKT signaling pathway and GLUT 4 expression. *FEBS Open Bio.* 2019;9(5):1008–19.
187. Li X, Wen H, Zhang Y, Liu A, Zhang X, Fu M, et al. DPHB, a diarylheptane from *alpinia officinarum* hance, ameliorates insulin resistance: a network pharmacology and in vitro study. *Front Pharmacol.* 2022;13:1–16.
188. Zhang X, Zhang Y, Zhou M, Xie Y, Dong X, Bai F, et al. DPHC from *alpinia officinarum* ameliorates oxidative stress and insulin resistance via activation of Nrf2/ARE pathway in db/db mice and high glucose-treated hepG2 cells. *Front Pharmacol.* 2022;12:1–15.
189. Telapolu S, Kalachavedu M, Punnoose AM, Bilikere D. MD-1, a poly herbal formulation indicated in diabetes mellitus ameliorates glucose uptake and inhibits adipogenesis – an in vitro study. *BMC Complement Altern Med.* 2018;18(1):1–11.

190. Ghasemi, Asghar; Sajad JKK. Review article : the laboratory rat : age and body weight matter. EXCLI J 2021;201431-1445. 2021;2005:1431–45.